Please assess the completion status of the following clinical trial:

Trial Title: Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with an dual chamber ICD or CRTD (with an existing functional atrial lead) with remote monitoring capabilities and EF \<= 40% within the last 3 months by echocardiogram, nuclear imaging, MRI or cardiac catheterization,~2. Persistent or chronic symptomatic AF resistant to anti-arrhythmic medication other than Amiodarone. Resistant defined as recurrent AF of greater than 5 minutes duration at least once per month.~3. Therapeutic anticoagulation for at least three weeks prior to initiation of therapy~4. Ability to complete 6 minute walk test.~5. Age \>= 18 years old. (Females must be either post-menopausal \>12 months, practicing a protocol-acceptable method of birth control \[defined as injectable or implantable hormonal contraceptives, oral contraceptives, intrauterine device, diaphragm plus spermicide\], or have had a hysterectomy, bilateral oophorectomy, or tubal ligation performed at least 6 months prior to enrollment).~6. All patients optimized on CHF medications including beta-blocker and ace-inhibitor or angiotensin-receptor blocker.~7. patients receiving low dose amiodarone- \<200 mg for 2 or less months~Exclusion Criteria:~The exclusion criteria are:~1. Reversible causes of AF such as pericarditis, hyperthyroidism,~2. Presently with Valvular Heart disease requiring surgical intervention~3. Presently with coronary artery disease requiring surgical intervention~4. Early Post-operative AF (within three months of surgery)~5. Previous MAZE or left atrial instrumentation~6. Prolonged QT interval~7. Hypothyroidism~8. Liver Failure~9. Life expectancy \<= 2 years~10. Social factors that would preclude follow up or make compliance difficult.~11. Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin~12. Enrollment in another investigational drug or device study.~13. Patients with severe pulmonary disease i.e. COPD or asthma~14. Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction~15. Any ophthalmologic disorders (other than requiring glasses for vision correction)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AF ablation (Type: ACTIVE_COMPARATOR): Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting.
- Amiodarone (Type: ACTIVE_COMPARATOR): Amiodarone is taken orally on a daily basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).